PIK3CA-related overgrowth spectrum (PROS): Diagnostic and testing eligibility criteria, differential diagnosis, and evaluation

Keyphrases

• Activating mutation 66%
• Approaches to Assessment 33%
• Associated Complications 33%
• Capillary Malformation 33%
• Clinical Diagnosis 33%
• Clinical Diagnostics 33%
• Clinical Entities 33%
• Clove 33%
• CLOVES Syndrome 33%
• Consensus Document 33%
• Diagnostic Criteria 33%
• Diagnostic Features 33%
• Differential Diagnosis 100%
• Differential Evaluation 100%
• Epidermal Nevus 33%
• Extreme Difference 33%
• Familial multiple Lipomatosis 66%
• Fibroadipose Hyperplasia 33%
• Genotype 33%
• Hemihyperplasia 66%
• Infiltrating Lipomatosis 33%
• Lipomatous Overgrowth 33%
• Macrodactyly 66%
• Megalencephaly 100%
• Molecular Diagnostics 33%
• Mutation Burden 33%
• National Institutes of Health 33%
• Natural History 33%
• Overgrowth 100%
• Overgrowth Disorder 33%
• Patient Advocacy Groups 33%
• Patient Support 33%
• Pharmacological Therapy 33%
• Phenotypic Spectrum 33%
• Phosphoinositide 3-kinase (PI3K) 33%
• PI3K-AKT-mTOR Pathway 33%
• PIK3CA 66%
• PIK3CA mutation 33%
• PIK3CA-related Overgrowth Spectrum 100%
• Scoliosis 33%
• Segmental Overgrowth 33%
• Somatic Overgrowth 33%
• Spectroscopic Diagnostics 100%
• Surgical Management 33%
• Testing Approaches 33%
• Thrombosis Risk 33%
• Uniform Approach 33%
• Vascular Anomalies 33%
• Vascular Malformation 33%

Medicine and Dentistry

• Alexander Disease 100%
• Capillary 25%
• Congenital Malformation 25%
• Diagnosis 100%
• Differential Diagnosis 100%
• Disease 50%
• Hyperplasia 25%
• Lipomatosis 75%
• Macrodactyly 50%
• Mammalian Target of Rapamycin 25%
• Molecular Diagnosis 25%
• Nevus 25%
• Patient Advocacy 25%
• Phosphoinositide 3-Kinase 25%
• Scoliosis 25%
• Somatics 75%
• Surgery 25%
• Thrombosis 25%
• Vascular Anomaly 50%